Descripción de la empresa
Sarepta Therapeutics, Inc. operates as a commercial-stage biopharmaceutical entity dedicated to the discovery and development of RNA-targeted therapeutics, siRNA platforms, gene therapies, and other genetic therapeutic modalities specifically designed for the treatment of rare diseases. The company functions within the Healthcare sector and the Biotechnology industry, positioning itself at the intersection of advanced scientific innovation and specialized patient populations. According to the available financial data, the firm holds a market capitalization of $2.42B, generates annual revenue of $2.20B, and employs a workforce of 835 individuals. These valuation and revenue figures indicate that Sarepta maintains a substantial enterprise presence despite operating in a niche market segment focused on rare genetic conditions, reflecting significant investor confidence in its proprietary asset pipeline and operational scale.
Salud financiera
The company reported a revenue of $2.20B over the trailing twelve months, yet it recorded a net income of $-713,409,984 and an EBITDA of $-613,251,008, revealing a substantial gap between top-line sales and bottom-line profitability that points to a heavy cost structure driven by research and development expenditures. Despite the reported net loss, the firm generated a positive free cash flow of $95.92M, which suggests a degree of financial flexibility allowing for capital allocation toward strategic initiatives without immediate reliance on external equity financing. The gross margin stands at -7.4%, while the operating margin is -92.6% and the profit margin is -32.5%; these negative figures highlight the high burn rate inherent in biotechnology firms during the commercialization phase before achieving widespread market penetration or cost efficiencies. On the balance sheet, the company holds $939.65M in cash against $1.04B in debt, resulting in a debt-to-equity ratio of 91.14, which indicates a highly leveraged position relative to its equity base. However, the current ratio of 2.32 demonstrates robust short-term liquidity, as current assets significantly exceed current liabilities, ensuring the ability to meet obligations due within a year. Furthermore, the return on equity is -53.5% and the return on assets is -11.2%, metrics that reveal that management has not yet generated positive returns on shareholder capital or total assets, a common characteristic for biotech companies still in the growth and expansion phases.
Evaluación de valoración
Sarepta Therapeutics presents a trailing P/E ratio of N/A due to its negative earnings, whereas the forward P/E is listed at 7.59, implying that the market prices the stock based on anticipated future profitability rather than current historical performance. The price-to-book ratio is 2.12, indicating that the market values the company at a premium of roughly two times its net asset value, which often reflects the high value of intangible assets like intellectual property and patent portfolios. Alternative valuation metrics such as the price-to-sales ratio of 1.10 and an EV/EBITDA of -4.11 provide further context, suggesting the market is willing to pay over one dollar for every dollar of sales generated, while the negative EV/EBITDA underscores the current lack of earnings power. The stock has traded between a 52-week high of $64.80 and a 52-week low of $10.42, a range that illustrates significant price volatility typical of smaller-cap biotechnology stocks. With a beta of 0.28, the stock exhibits low price volatility relative to the broader market, moving less dramatically than the S&P 500 and suggesting a defensive characteristic often seen in companies with specific, non-correlated revenue streams.
Growth & Income
The company experienced a revenue growth of -32.7% year-over-year, while earnings growth is listed as N/A due to the absence of positive earnings in the prior period; this contraction in revenue indicates a decline in sales volume or pricing power rather than an expansion of the commercial footprint. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, meaning the firm retains all generated cash to reinvest into its pipeline rather than returning value to shareholders through dividends. The overall growth and income profile is characterized by revenue contraction and a lack of current income generation, reflecting the transitional nature of the business as it navigates between high R&D investment periods and potential future profitability.